Welcome to the 4th Treg Directed Therapies Summit
2022 remains a pivotal year for Treg directed therapies, with several trials due to read-out, and as we await the much-anticipated clinical proof of concept, the opportunity in this space is exploding as we begin to see the potential of Treg therapies in autoimmune, transplant, and inflammation.
The 4th Treg Directed Therapies Summit returns to Boston bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is your unique opportunity to unite senior-level executives from key large pharma, biotech, academia and solution providers to discuss how to target Treg-modifying therapies with enhanced persistence and durability safely and at scale.
5 Reasons You Can’t Afford to Miss it:
Join industry pioneers to benchmark fundamental Treg interactions and biology to optimize target validation for selective Treg targeting and biomarker strategy with Tom Malek, Michael Rosenblum and Mozart Therapeutics
Learn from failed IL-2 trials to fuel further R&D & plan for large-scale trials to advance efficacious therapies to patients with Sonoma, Gilead Sciences and GlaxoSmithKline
Maintain stability and function of expanded Tregs to ensure persistence, prevent relapse & overcome resistance with Quell Therapeutics, TCR2 and Nektar Therapeutics
Optimize drug design and formulation to drive sustained antigen specific responses for selective Treg targeting with Roche, Abata and EpiVax
Engineer Tregs for increased selectivity, maximal tolerance induction and highest clinical impact with Genti Bio, Kynerva Therapeutics and Stanford University